Items tagged with Access

Global campaign launched urging Johnson & Johnson to reduce price of bedaquiline (post with simple image)

Médecins Sans Frontières launches a global campaign calling on Johnson & Johnson to lower the price of bedaquiline to no more than US$1 per day.

Time to lower the price of Xpert cartridges to US$ 5 (post with simple image)

Advocates request Cepheid immediately reduce the price of Xpert tests to US$ 5, inclusive of service and maintenance; the company responds they are “not able to predict the amount of further reductions or when they may be available.”

DR-TB Drugs Under the Microscope, 6th edition (post with simple image)

Médecins Sans Frontières releases the 6th edition of DR-TB Drugs Under the Microscope: 5 Urgent Actions to Improve DR-TB Treatment.

Civil society demands affordability, transparency and accountability from the TB Alliance (post with simple image)

Civil society activists storm the stage at The Union Conference to demand affordability, transparency and accountability from the TB Alliance.

TB activists disrupt opening of The Union Conference to protest drug corporations keeping life-saving medicines from people (post with simple image)

Newer medicines for drug-resistant TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world. 

Price announced for new lifesaving TB drug pretomanid still too high (post with simple image)

Pretomanid is just one part of a regimen of multiple drugs that people need. MSF has been calling for the price of a complete DR-TB treatment course to be no higher than $500 per person.

Civil society statement on rifapentine price discount (post with simple image)

A lower price for rifapentine is just a start — communities need more than discounts to access TB preventive therapy!

Protestors demand Cepheid halve the price of GeneXpert TB tests to US$5 (post with simple image)

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Public investments in TB medicine bedaquiline far exceed those of developer Johnson & Johnson (post with simple image)

Quantification of investments in the development of bedaquiline finds total public and philanthropic expenditures are three to five times those of Johnson & Johnson.

Page 61 of 61 · Total posts: 0

←First 60 61